Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-29
2005-11-29
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S360000
Reexamination Certificate
active
06969718
ABSTRACT:
There are disclosed compounds of the formula (I):prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases.
REFERENCES:
patent: 5350852 (1994-09-01), Emonds-Alt et al.
patent: 5432175 (1995-07-01), Piwinski et al.
patent: 5620989 (1997-04-01), Harrison et al.
patent: 5654316 (1997-08-01), Carruthers et al.
patent: 5665735 (1997-09-01), Friary et al.
patent: 5688960 (1997-11-01), Shankar
patent: 5691362 (1997-11-01), McCormick et al.
patent: 5696267 (1997-12-01), Reichard et al.
patent: 5719156 (1998-02-01), Shue et al.
patent: 5760018 (1998-06-01), Baker et al.
patent: 5783579 (1998-07-01), McCormick
patent: 5789422 (1998-08-01), Reichard et al.
patent: 5795894 (1998-08-01), Shue et al.
patent: 5840725 (1998-11-01), Reichard et al.
patent: 5892039 (1999-04-01), Shue et al.
patent: 5945428 (1999-08-01), Shih et al.
patent: 5968929 (1999-10-01), Blythin et al.
patent: 6063926 (2000-05-01), Reichard et al.
patent: 6204265 (2001-03-01), Reichard et al.
patent: 1930818 (1970-01-01), None
patent: 2304153 (1974-08-01), None
patent: 0655442 (1995-05-01), None
patent: 2215235 (1974-08-01), None
patent: WO86/01105 (1986-02-01), None
patent: WO90/10462 (1990-09-01), None
patent: WO91/00731 (1991-01-01), None
patent: WO91/00733 (1991-01-01), None
patent: WO 92/06971 (1992-04-01), None
patent: WO 93/20063 (1993-10-01), None
patent: WO94/10165 (1994-05-01), None
patent: WO94/13639 (1994-06-01), None
patent: WO94/26767 (1994-11-01), None
patent: WO94/29309 (1994-12-01), None
patent: WO95/19344 (1995-07-01), None
patent: WO96/26201 (1996-08-01), None
patent: WO 96/31501 (1996-10-01), None
patent: WO97/11162 (1997-03-01), None
patent: WO 00/39119 (2000-07-01), None
patent: WO00/43008 (2000-07-01), None
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Hawley's Condensed Chemical Dictionary, 12th ed., Richard J. Lewis, Sr. , © 1993 by Van Nostrand Reinhold. p. 594.
Concise Chemical Dictionary, edited by Drs. Hans-Dieter Jakubke and Hans Jeschkeit, © 1993 by Walter de Gruyter & Co., p. 490.
McGraw-Hill Dictionary of Chemical Terms, 3rd ed. edited by Sybil P. Parker, © 1984 McGraw-Hill, Inc., p. 200.
Poirier, Donald, “Inhibitors of 17-beta-Hydroxysteroid Dehydrogenases” Current Medicinal Chemistry, vol. 10, pp. 453-477 (2003).
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed., pp. 1635-1648, McGraw-Hill Medical Publishing Division © 2001.
The Merck Manual, 16th ed., pp. 1092-1093, 2277-2278 and 2429-2431, Merck Research Laboratories, Merck & Co., Rahway, NJ © 1992.
Smith et al, “Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers” Expert Opinion on Therapeutic Patents, vol. 11(5), pp. 789-824 (2001).
Debeljuk, L., Lasaga, M.,Modulation of the hypothalamo-pituitary-gonadal axis and the pineal gland by neurokinin A, neuropeptide K and neuropeptide γ, Peptides 20 (1999), 285-299.
Guzi Timothy J.
Paruch Kamil
Albanese Margaret M.
Kalyanaraman Palaiyur S.
Kutzenco Allan N.
Schering Corporation
Tucker Zachary C.
LandOfFree
17-β hydroxysteroid dehydrogenase type 3 inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 17-β hydroxysteroid dehydrogenase type 3 inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 17-β hydroxysteroid dehydrogenase type 3 inhibitors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3457811